FDA Approves Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria
In a decision that expands the April 2025 approval of dupilumab (Dupixent, Regeneron/Sanofi) for chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older, the U.S. Food






